About this document
Nature 09454 by Ana Thereza Fiori is a document available to read on EtoBox.
The study investigates the clinical efficacy of PLX4032, a RAF inhibitor, in treating BRAF-mutant melanoma, demonstrating its ability to selectively block the RAF/MEK/ERK pathway and induce tumor regression in preclinical models. Phase 1 clinical trials revealed a high response rate in patients with BRAF mutations, with significant tumor regressions observed at optimal dosing. The findings underscore the importance of targeting BRAF kinase activity for effective treatment of BRAF-mutant melanoma.
- Author
- Ana Thereza Fiori
- Language
- EN